Amgen Surpasses Expectations with Strong Q2 | Business and Finance News

Amgen crushed Q2 expectations with $10.5B in revenue and $6.29 EPS, fueled by double-digit growth from Repatha and TEZSPIRE—17 of their drugs now earn over $1 billion annually. They’ve raised full-year guidance, signaling confidence. Analysts grilled management on MariTide’s safety monitoring, which was reassured by active data safety committees. Otezla remains a top first-line treatment despite new competitors squeezing pricing. Investors are watching key trial readouts for MariTide and Olpasiran, plus manufacturing scalability and payer access for existing blockbusters. Amgen’s strategy is clear: outperforming markets while navigating headwinds. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/fbb368ddcc1c7bb3